Articles tagged with Hepatocellular Carcinoma
A Singapore clinical trial has introduced a new way to treat advanced hepatocellular carcinoma by combining nivolumab, an immunotherapy drug, with yttrium-90 resin microspheres radioembolisation. The study shows promising results in treating intermediate and advanced HCC, with an overall response rate of 30.6%.
A new analysis of US national data finds that external-beam radiation therapy is a proven treatment option for patients with unresectable liver cancer but is rarely prescribed, with only 3.6% of patients receiving it. The study suggests that institutional and regional practice patterns play a key role in driving treatment decisions.
A study published in The Journal of Nuclear Medicine found that PSMA PET/CT is more accurate than conventional CT in detecting hepatocellular carcinoma metastases. This led to a change in management plans for nearly half of the patients, enabling them to receive effective treatment.
A collaborative research between Owkin and Cleveland Clinic has developed an AI model that predicts liver cancer recurrence following liver transplantation. The model outperformed traditional scoring systems and showed promise for improving patient outcomes.
A recent study published in AJR found that gallbladder polyps can fluctuate significantly in size and number over time. The authors suggest revising guidelines to reflect this variability, with no cases of gallbladder carcinoma identified in patients who underwent cholecystectomy.
The most common form of liver cancer is on the rise in rural areas, with men aged 60-69 and non-Hispanic Blacks disproportionately affected. Urban areas, however, have seen a decline in HCC rates since 2013, including among younger individuals and certain ethnic groups.
Research from Osaka City University reveals that hepatocellular carcinoma survival decreases as poorly differentiated tumor size increases. Tumors over 5cm have a significantly higher risk of early recurrence and spreading to other parts of the body.
Researchers identified a hub candidate network involving RNA binding protein interacting with circular RNA in hepatocellular carcinoma. The study provides insights into the mechanism of HCC and potential biomarker identification.
Researchers found that miR-513b-5p attenuates autophagy and tumor growth in liver cancer cells by targeting PIK3R3. The study suggests miR-513b-5p as a promising therapeutic target for hepatocellular carcinoma.
Researchers have shown that targeted radio-wave therapy is safe and effective in treating hepatocellular carcinoma (HCC), the most common type of liver cancer. The therapy improved overall survival by more than 30% in patients with well-preserved liver function, as well as those with more severe disease.
Researchers have identified distinct metabolic phenotypes in hepatocellular carcinoma subtypes, providing insights into precise personalized treatment options. The study revealed a poor prognosis subtype strongly correlated with immune pathway up-regulation and unsaturated fatty acid accumulation.
The study investigated the association of the IGF/CTP score with overall survival and progression-free survival in CTP class A patients with advanced HCC treated with sorafenib. In these patients, IGF/CTP score B was associated with shorter PFS and OS, indicating a more accurate predictive tool for treatment outcomes.
A recent genetic study published in PLOS Genetics has identified MAGEA3, a gene associated with poor prognosis in liver cancer, as a potential target for new treatments. The study found that blocking the expression of MAGEA3 in liver cancer cells can prevent their growth and death, offering hope for developing new therapies.
Research reveals liver cancer incidence is 2.6 times higher in Indigenous Australians compared to non-Indigenous patients. Mobile liver clinics and regular ultrasound surveillance can help prevent the disease, according to expert calls for action.
This study investigated the effect of culturing hepatocellular cancer cells in more native conditions, revealing slower doubling times, increased glycolytic enzymes, and mutations in mitochondrial DNA. The results showed increased resistance and sensitivity for cells cultured in native conditions, highlighting new insights into tumor b...
The study found that hepatocellular carcinoma develops on a background of chronic inflammation and fibrosis, with tumor-associated macrophages playing a key role. The researchers characterized the inflammatory microenvironment in two HCC mouse models, revealing divergent phenotypes of liver macrophage subsets and their contribution to ...
Researchers discovered that a Western diet high in fat and cholesterol can lead to obesity, diabetes, and Non-alcoholic steatohepatitis (NASH), which progresses to liver cancer, kidney disease, and cardiovascular disease. Switching to a normal chow diet improves NASH and liver fibrosis, prevents cancer progression and mortality.
A study published in Oncotarget found a distinct global DNA hypermethylation pattern and gene expression signature in liver cancer among patients with Indigenous American ancestry. This molecular subtype of HCC preferentially affects people with Indigenous ancestry, highlighting the importance of considering anthropological background ...
A Mount Sinai study found immunotherapy to be significantly less effective in liver cancer patients with non-alcoholic steatohepatitis (NASH), while also fueling tumor growth. The research highlights the need for refined therapeutic strategies to treat both tumors and underlying liver disease.
Researchers identified three m6A modification patterns in HCC, each with distinct metabolic characteristics. These patterns were associated with differences in tumor stage, prognosis, and response to treatment. The study provides novel insights into potential prognostic markers and response to treatment in patients with HCC.
The IMbrave150 trial found that the atezo+bev combination provided a median overall survival of 19.2 months, surpassing the 13.4-month median for those treated with sorafenib alone. The treatment also showed improved survival rates at 18 months, with 52% of patients on atezo+bev remaining alive compared to 40% on sorafenib.
Researchers at Osaka University discovered that liver cancer cells induce autophagy in nearby stromal cells, leading to the secretion of GDF15, which enhances tumor growth. High levels of GDF15 are associated with a poorer prognosis in HCC patients.
Osaka University researchers developed a technique to study liver cancer genes in lab mice, identifying a serum biomarker for effective treatment. The study found that FGF19-driven HCC is susceptible to lenvatinib treatment and a specific protein, ST6GAL1, can be used as a biomarker.
Researchers at Massachusetts General Hospital have identified a combination therapy that improves survival in mouse models of hepatocellular carcinoma. The dual therapy combines regorafenib to reprogram the tumor immune microenvironment and PD1 antibodies to stimulate anti-tumor immunity.
The study developed a reliable method for creating porcine hepatocellular carcinoma cells, which exhibited similar characteristics to human HCC cells. The Oncopig model was shown to be a valuable tool for testing innovative therapeutic modalities and correlative studies for new therapies.
Emerging treatments for liver cancer show promising safety results, with atezolizumab and bevacizumab combination therapy improving overall survival. Lenvatinib and pembrolizumab combination also demonstrates efficacy in Phase 1b study, while nivolumab + ipilimumab combination yields encouraging results in subgroup analysis.
Researchers developed new predictive models to identify patients at highest risk of developing hepatocellular carcinoma (HCC) after successful hepatitis C virus (HCV) treatment. The models used clinical parameters and identified specific clusters of patients with elevated or impaired liver function, suggesting more personalized HCC sur...
Scientists have identified a microRNA in obese mouse mothers that increases the odds of liver cancer in their offspring and throughout future generations. The study found that maternal obesity causes susceptibility to liver cancer in offspring, with the severity increasing over generations.
Researchers developed a blood test that detects viral exposure signatures linked to liver cancer risk. The test showed high accuracy in distinguishing patients with hepatocellular carcinoma from those with chronic liver disease and healthy volunteers. It has the potential to improve liver cancer screening and early detection.
A study found that people infected with Hepatitis D have up to three times the risk of developing hepatocellular carcinoma compared to those infected only with Hepatitis B. Researchers are calling for increased awareness and screening of Hepatitis D in patients with Hepatitis B.
A new study found that exercise can prevent the development of liver cancer in obese mice with fatty liver disease. The research suggests that voluntary exercise exerts its protective effects via molecular signaling pathways, including tumor suppressor gene p53 and stress-activated protein kinase JNK1.
Research found that higher levels of sBTLA proteins were associated with poorer overall survival in patients with advanced liver cancer. Treatment with sorafenib revealed dynamic changes in soluble checkpoint protein levels, suggesting potential use as a biomarker for predicting patient outcomes.
Scientists at UNIGE discovered a protein, S100A11, that promotes inflammation and build-up of fibrous tissue in the liver, increasing cancer severity. The presence of S100A11 in blood may enable early detection through simple blood sampling, paving the way for targeted therapies.
A nationwide population-based study found that firearms are the most lethal method for suicide, with nearly 9 out of 10 attempts being fatal. The overall fatality rate for suicide attempts nationwide is 1 out of 12. The study suggests that prevention efforts focused on reducing access to firearms could save lives.
A phase 3 study showed that combining PD-L1 inhibitor atezolizumab and VEGF inhibitor bevacizumab significantly improved overall survival and progression-free survival in patients with unresectable HCC. The treatment combination also increased overall response rate and delayed deterioration in quality of life.
The incidence of liver cancer has tripled in the UK over the past 20 years, with the majority of cases diagnosed in men. The most deprived fifth of the population accounts for 25% of HCC cases, many of which have cirrhosis and are not treatable by surgery due to advanced scarring.
Researchers identified CEUS biomarkers predicting HCC in cirrhotic nodules, stratifying risk within the LI-RADS system. Customized surveillance strategies can be enabled using these biomarkers.
A new study found that DNA mutations common in liver cancer are also present in healthy livers, accumulating over time to lead to chronic liver disease. The study provides unprecedented detail on how these genetic changes develop and offers a potential way to predict individual risk of liver cancer.
A nationwide cohort study found that lipophilic statin use was associated with significantly lower risk of hepatocellular carcinoma (HCC) incident, all-cause death, and liver-related death. The benefits were dose and duration-dependent, with the greatest reduction in HCC risk occurring after at least 600 cumulative defined daily doses.
A retrospective review of 304 patients found that aspirin therapy improved lab values and overall survival post-TAE for HCC, with lower bilirubin levels at 1 day, 1 month, and 1 year after embolization. Aspirin use was also associated with longer median overall survival period after TAE.
Researchers found that radio waves targeting a specific calcium channel can block the growth of liver cancer cells without damaging healthy cells. The treatment, approved for use in Europe, uses a handheld device that emits radio frequencies via a spoon-shaped element placed on the patient's tongue.
Researchers discover parvifoline AA, a natural compound, stimulates NKG2D ligands on cancer cells, making them more recognizable and targetable by NK cells. This increases the effectiveness of NK cell-based tumor immunotherapy.
A study published at the ARRS 2019 Annual Meeting found that stereotactic body radiation therapy (SBRT) is an effective locoregional treatment option for hepatocellular carcinoma (HCC), with a low local progression rate. The results also corrected standard response assessment interpretations, suggesting that persistent arterial phase e...
A study comparing percutaneous liver ablation interventions (IRs) to surgical procedures for hepatocellular carcinoma (HCC) found IRs had significantly lower inhospital mortality rates and hospitalization costs. IRs were also associated with shorter lengths of stay and a higher routine discharge rate to home.
Researchers found that serum AKR1B10 levels were significantly associated with advanced liver fibrosis stages, particularly stage 4. The protein's origin was confirmed via immunohistochemical staining, and its combination with WFA(+)-M2BP showed high sensitivity and specificity for predicting NASH fibrosis and life-threatening events.
Researchers at TGen identified AKR1B10 as a potential biomarker for liver cancer diagnosis and prognosis. The enzyme has a paradoxical role in HCC development, where its overexpression indicates cancer presence while suppression may slow progression.
Researchers at CNIC have discovered a hormone called adiponectin that protects the liver from liver cancer, which affects more men than women. Adiponectin is produced in higher amounts in women and slim people, with levels declining after puberty in men.
Researchers discovered that adiponectin, a hormone secreted by fat cells, protects female mice from liver cancer. In contrast, increased testosterone levels in male rodents reduce tumor growth and lower adiponectin levels.
Researchers have engineered HBV-specific T cells to treat Hepatocellular carcinoma, a commonly occurring liver cancer. The treatment was individualised and showed promise in reducing tumour size in patients with HBV-related liver cancer.
Researchers report an assay that uses cell-free DNA mutations and protein biomarkers to detect hepatocellular carcinoma in asymptomatic individuals. In a sample of 331 hepatitis B virus-infected individuals, the assay correctly identified 17% who had liver cancer without symptoms.
A large study found an association between whole grain and high dietary fiber intake with a lower risk of hepatocellular carcinoma. The findings suggest that incorporating more whole grains into the diet may help reduce liver cancer risk.
A research team at Tokyo Medical and Dental University classified hepatocellular carcinoma into three distinct subgroups based on mutation patterns, gene expression, and immune system characterization. The findings suggest that each subgroup has a unique clinical profile, enabling targeted treatment approaches.
Jun Ho Lee, a doctoral student at UNIST, received the grand prize of $10,000 from Merck's 2018 Life Science Awards in Tumor Biology. His research on TonEBP expression in hepatocellular carcinoma has shown promise in predicting patient prognosis and preventing cancer recurrence.
Researchers analyzed national data and found that African-American transplant recipients lived 4.75 years longer on average if their livers were donated by someone of the same race. The study suggests a possible way to improve survival rates for this patient population, which typically faces poorer outcomes with liver cancer.
Researchers from KAIST have identified novel pathways involving T immune cell exhaustion in liver cancer patients. The study provides evidence for designing optimal strategies for immune checkpoint blockades and offers a new path for customized medicine.
Researchers at Kanazawa University identify osteopontin as a key player in HCV replication and stemness in cancer stem cells. The study reveals that osteopontin regulates HCV replication, tumor initiation, and metastasis through the OPN-CD44 axis.
A preclinical study found that inhibiting liver cancer cell growth can be achieved by manipulating the circadian clock. Fifty percent of liver tumors express a malfunctioning protein that induces circadian dysfunction, and forcing tumor cells to re-express this protein leads to their death.
A new study has identified glycolytic enzymes as potential biomarkers for early detection and prevention of liver cancer. The research found that the shift to glycolysis in cirrhotic livers is associated with a higher risk of developing hepatocellular carcinoma, offering hope for improved early detection and treatment.
Researchers identified Sav1, a component of the Hippo pathway, as a key mutated gene in fatty liver-associated liver cancer. This discovery may lead to new liver cancer treatments targeting the Hippo pathway.
A Massachusetts General Hospital-led study found that regular aspirin use can significantly reduce the risk of developing primary liver cancer. The study analyzed data from over 133,000 participants and found a 49% reduction in relative risk for those taking two or more standard-dose tablets a week.